BMS’s Opdivo On Track For Esophageal Cancer Indication
Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.
You may also be interested in...
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.
Merck & Co is working hard to extend the indications for Keytruda, and reports the checkpoint inhibitor significantly improves overall survival and PFS when combined with chemotherapy in the first-line treatment of metastatic esophageal cancer.
Keeping Track: US FDA Approvals Include Novel Agents Zepzelca And Uplizna, Biosimilar Nyvepria, Follow-On Semglee
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.